Biolegend, 312714, Brilliant Violet 421™ anti-human CD158e1 (KIR3DL1, NKB1) Antibody, 100tests

CD158e1, also known as NKB1, is a 70 kD member of the immunoglobulin superfamily that is expressed on a subset of natural killer cells and T cells at varying levels among individuals. NKB1 is a type I membrane protein containing two immunoglobulin C2-type domains. The interaction of NKB1 with specific HLA-B antigens on a target cell (the HLA-Bw4 allele, for example) inhibits cytotoxicity and prevents target cell lysis and death. The interactions between KIR and MHC class I are thought to be important in NK and T cell regulation following antigen stimulation. The absence of ligands for KIRs may lower the threshold for activation through activating receptors and increase inflammation and susceptibility to autoimmune disease.
100tests
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Human NK cell clone VL186-1.6
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: The DX9 antibody reacts with the KIR (killer cell inhibitory receptor) designated NKB1 or KIR3DL1. Additional reported applications (for the relevant formats) include: immunoprecipitation1 and restoring the NK cell cytotoxicity4,8. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 312710).
Application References(PubMed link indicates BioLegend citation): Litwin V, et al. 1994. J. Exp. Med. 180:537. (IP) Gumperz J, et al. 1996. J. Exp. Med. 183:1817. Gardiner CM, et al. 2001. J. Immunol. 166:2992. Bakker ABH, et al. 1998. J. Immunol. 160:5239. Goodier M, et al. 2000. J. Immunol. 165:139. Kirwan SE and Burshtyn DN. 2005. J. Immunol. 175:5006. (FC) Yawata M, et al. 2002. Immunogenetics 54:543. Valiante NM, et al. 1997. Immunity 7:739. Pascal V, et al. 2007. J. Immunol. 179:1625. (FC) PubMed Lichterfeld M, et al. 2008. J. Exp. Med. 204:2813. (FC) PubMed Luetke-Eversloh M, et al. 2014. PLoS Pathog. 10:1004441. PubMed Purdy AK, et al. 2014. J Immunol. 193:4675. PubMed
Product Citations: Marquardt N, et al. 2015. J Immunol. 195: 3262 - 3272. PubMed Jo DH, et al. 2023. Mol Ther Methods Clin Dev. 29:173. PubMed Höfle J, et al. 2022. EMBO Rep. 23:e54133. PubMed Li H, et al. 2018. PLoS Genet. 14:e1007163. PubMed Manser AR, et al. 2019. J Immunol. 203:2301. PubMed Lisovsky I, et al. 2015. J Virol. 89: 9909 - 9919. PubMed Guo M, et al. 2021. Front Oncol. 11:632540. PubMed Lutter L, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1567. PubMed Mishra HK, et al. 2021. Front Immunol. 12:711621. PubMed Lisovsky I, et al. 2015. J Leukoc Biol. 97:761. PubMed Isitman G, et al. 2016. PLoS One. 11:e0164517. PubMed Boudreau J, et al. 2014. PLoS One. 9:99543. PubMed Terszowski G, et al. 2014. J Immunol. 192:5618. PubMed Purdy A, et al. 2014. J Immunol. 193:4675. PubMed
RRID: AB_10897807 (BioLegend Cat. No. 312713) AB_2561652 (BioLegend Cat. No. 312714)
Structure: Immunoglobulin superfamily member, contains two immunoglobulin C2-type domains, 70 kD type I membrane protein
Distribution: Subset of NK and T cells
Function: Inhibits cytotoxic function of NK and T cells upon interacting with specific HLA-B antigens on target cell
Ligand/Receptor: HLA-B antigens such as the HLA-Bw4 allele
Cell Type: NK cells, T cells
Biology Area: Immunology
Molecular Family: CD Molecules
Antigen References: 1. Colonna M, et al. 1995. Science 268:405. 2. D'Andrea A, et al. 1995. J. Immunol.. 155:2306. 3. Uhrburg M, et al. 1997. Immunity 7:753. 4. Gumperz JE, et al. 1996. J. Exp. Med. 183:1817. 5. Wagtmann N, et al. 1995. Immunity 3:801.
Gene ID: 3811
UniProt: View information about CD158e1 on UniProt.org
Clone: DX9
Regulatory Status: RUO
Other Names: NKAT3, NKB1, KIR-NKB1, p70
Isotype: Mouse IgG1, κ
Q: What is the F/P ratio range of our BV421™ format antibody reagents?
A: It is lot-specific. On average it ranges between 2-4.